Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG) Q425
Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached $2.5M and FY25 total revenue reached $10.2M, including $6.8M of ZUNVEYL sales. More importantly, demand indicators continued to inflect, with bottles dispensed rising 62% q/q to 4,941 with December alone reaching a record 1,859 bottle. Repeat […]
Stonegate Capital Partners Updates Coverage on Heliostar Metals Ltd (TSXV: HSTR) 3Q26
Heliostar continued advancing its flagship Ana Paula project in Guerrero as its primary development asset and next major source of growth. The November 2025 PEA outlined a nine-year underground mine producing 101.1 koz of gold per year after ramp-up, with cash costs of $923/oz and AISC of $1,011/oz. At $2,400/oz gold, the study generated an […]
Stonegate Capital Partners Updates Coverage on Fold Holdings Inc. (NASDAQ: FLD) Q425
Fold exited FY25 with solid momentum, delivering revenue of $31.8M (+34% y/y) on transaction volume of $960M (+46% y/y) and ending the year with more than 84K (+20% y/y) verified accounts, including ~13K net adds. While profitability remained pressured by ongoing investment, with operating loss of $(27.7)M and adj. EBITDA of $(17.2)M, the year still […]
Stonegate Capital Partners Initiates Coverage on MarketWise (NASDAQGM: MKTW)
MarketWise exited FY25 with a stronger operating profile, as improving demand and execution helped offset the lagged impact of weaker prior-period billings on reported revenue. FY25 billings increased to $271.2M (+13.4% y/y) and CFFO improved to $46.0M from $(22.2)M in FY24, while revenue declined to $328.1M (-19.7% y/y) and net income fell to $64.0M (-31.2% […]
Stonegate Capital Partners Updates Coverage on Sky Harbour Group Corporation (NYSE: SKYH) Q425
For FY25, Sky Harbour reported consolidated revenue of $27.5 million, up 87% year over year, including $21.6 million of rental revenue and $6.0 million of fuel revenue. Revenue growth was driven by a full year of contribution from CMA, increased occupancy at BNA, OPF, and SJC, and the commencement of operations at DVT, ADS, and […]
Stonegate Capital Partners Updates Coverage On Aemetis, Inc. (Nasdaq: AMTX) Q425
Aemetis’ 4Q25 results further support the view that the Company is beginning to transition from a capital-intensive buildout story toward a more monetizable low-carbon fuels platform. Dairy RNG remains the clearest proof point, with 12 operating digesters, approximately 405,000 MMBtu of full-year production, and 4Q output up 61% y/y. More importantly, Biogas contributed $10.3 million […]
Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (NYSE: SRFM) Q425
SRFM’s FY25 results suggest the company is emerging from restructuring with a more stable operating base and a clearer path to growth. Full-year revenue of $106.6M met the company’s raised outlook, while adjusted EBITDA loss improved to $41.7M on better airline operations, a stronger charter mix, and continued execution under the transformation plan. Net debt […]
Stonegate Capital Partners Updates Coverage on Aquafil S.p.A (BIT: ECNL) Q425
Aquafil’s FY25 results were better than the headline revenue decline suggests, as the year was defined more by mix, margin, and operating discipline than by top-line growth. Revenue fell 3.9% to €520.8M, largely reflecting lower raw material-linked selling prices. Volumes increased 4.4% on the year, leading to EBITDA increasing 16.1% to €72.4M representing EBITDA margin […]
Stonegate Capital Partners Updates Coverage on OppFi, Inc. (NYSE: OPFI) 4Q25
OppFi exited FY25 with strong momentum, delivering record revenue of $597.1M, adj net income of $139.8M, and adj EPS of $1.59, up 13.5%, 69.1%, and $0.64 y/y, respectively, while GAAP net income rose 74.4% to $146.2M. Results were driven by Model 6, broader use of risk-based pricing, and solid operating discipline, which improved unit economics […]
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)
NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The Company’s lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. It is designed to address key limitations of current treatment […]